GLP-1 Weight Loss Medications in Indiana

Indiana has a unique position in the GLP-1 landscape because Eli Lilly, the manufacturer of tirzepatide (Mounjaro and Zepbound), is headquartered in Indianapolis. This has led to higher local awareness of GLP-1 medications, active clinical trial participation at Indiana medical centers, and a provider community that is particularly familiar with the tirzepatide family. Local patient advocacy and employer health plan decisions are often influenced by Lilly proximity.

Indiana expanded Medicaid through HIP 2.0, which requires monthly contributions to a health savings account (POWER Account). HIP covers GLP-1 receptor agonists for type 2 diabetes management. Weight management coverage is more limited and requires prior authorization, documented BMI criteria, and evidence of lifestyle interventions. The POWER Account model means some medication costs flow through the health savings component.

Indianapolis has a strong healthcare ecosystem with IU Health, Ascension St. Vincent, and Community Health Network all offering weight management services. Outside Indianapolis, cities like Fort Wayne, South Bend, and Evansville have growing provider networks. Rural Indiana relies on telehealth for specialty access. The state participation in the Interstate Medical Licensure Compact broadens the pool of available telehealth providers.